{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:34:13Z","timestamp":1789752853724,"version":"4.0.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008478","name":"Wake Forest School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>The U.S. legal cannabis market is saturated with products containing high levels of tetrahydrocannabinol (THC), with no distinction between medical and recreational programs. This omnipresence of potent cannabis products seems to be driven by the recreational realm, where cannabis with the highest THC content is prized. This prevalence of highly potent cannabis is conveyed to medical programs, which places consumers (patients) at higher risk for over consumption and cannabis use disorder. Thus, understanding what factors influence the market that patients face in medical cannabis programs could shed light on the risks of legal cannabis. The supply and demand dynamic of the US for-profit cannabis market could explain the current market composition; therefore, we postulate that a financial gain could influence the perpetuation of the prevalence of high THC products in legal cannabis dispensaries. We investigate whether THC content in popular cannabis products correlates with higher prices and assess whether some attributes (type of product, chemovars, or presence of cannabidiol (CBD) affect the association of THC with price.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We focus on the world's largest cannabis market, California. We randomly selected dispensaries across the state, screened for a web presence and product menu, determined the most prevalent product type, and collected THC and CBD concentration, price, and other product attributes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We observed that herbal products were more common, they had THC concentrations greater than 10%, and THC concentrations positively correlated with price. This correlation existed in flower and preroll presentations, all chemovar, and independently of the level of CBD. CBD did not correlate with price; however, the presence of CBD diminished the THC and price correlation particularly in products with high THC (&amp;gt;15%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall, highly potent herbal cannabis products (&amp;gt;15% THC) are the majority of products offered and more expensive regardless of product type or chemovar in California dispensaries, suggesting that a financial gain contributes to the current market composition. Efforts to limit the availability of highly potent THC products and educate consumers about potential harms are needed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.893009","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:41:05Z","timestamp":1655451665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of Tetrahydrocannabinol Content and Price in Herbal Cannabis Products Offered by Dispensaries in California: A Purview of Consumers\/Patients"],"prefix":"10.3389","volume":"10","author":[{"given":"MaryBeth","family":"Dobbins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mannat","family":"Rakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Cunnane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"Pennypacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly G.","family":"Wagoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Reboussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Alfonso","family":"Romero-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/phar.2115","article-title":"Cannabis for chronic pain: challenges and considerations","volume":"38","author":"Romero-Sandoval","year":"2018","journal-title":"Pharmacotherapy."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut Syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.14740\/jocmr4090","article-title":"Dosage, Efficacy and safety of cannabidiol administration in adults: a systematic review of human trials","volume":"12","author":"Larsen","year":"2020","journal-title":"J Clin Med Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/phar.2469","article-title":"CBD and THC: do they complement each other like Yin and Yang?","volume":"40","author":"Pennypacker","year":"2020","journal-title":"Pharmacotherapy."},{"key":"B6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1212\/01.wnl.0000253187.66183.9c","article-title":"Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial","volume":"68","author":"Abrams","year":"2007","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"E694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial","volume":"182","author":"Ware","year":"2010","journal-title":"CMAJ."},{"key":"B8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jpain.2015.03.008","article-title":"Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy","volume":"16","author":"Wallace","year":"2015","journal-title":"J Pain."},{"key":"B9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jpain.2016.05.010","article-title":"An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease","volume":"17","author":"Wilsey","year":"2016","journal-title":"J Pain."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/ejp.1605","article-title":"The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: a randomized, double-blinded, placebo-controlled trial","volume":"24","author":"Almog","year":"2020","journal-title":"Eur J Pain."},{"key":"B11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","article-title":"Low-dose vaporized cannabis significantly improves neuropathic pain","volume":"14","author":"Wilsey","year":"2012","journal-title":"J Pain."},{"key":"B12","unstructured":"2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0230167","DOI":"10.1371\/journal.pone.0230167","article-title":"Mapping cannabis potency in medical and recreational programs in the United States","volume":"15","author":"Cash","year":"2020","journal-title":"PLoS ONE."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00406-019-00983-5","article-title":"New trends in cannabis potency in USA and Europe during the last decade (2008-2017)","volume":"269","author":"Chandra","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1001\/archpsyc.65.6.694","article-title":"Regional brain abnormalities associated with long-term heavy cannabis use","volume":"65","author":"Yucel","year":"2008","journal-title":"Arch Gen Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1017\/S0033291715001178","article-title":"Examining the profile of high-potency cannabis and its association with severity of cannabis dependence","volume":"45","author":"Freeman","year":"2015","journal-title":"Psychol Med."},{"key":"B17","first-page":"482","article-title":"The problem with the current high potency THC Marijuana from the perspective of an addiction psychiatrist","volume":"115","author":"Stuyt","year":"2018","journal-title":"Mo Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.drugalcdep.2018.11.012","article-title":"Higher average potency across the United States is associated with progression to first cannabis use disorder symptom","volume":"195","author":"Arterberry","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF03391701","article-title":"Why changes in price matter when thinking about Marijuana policy: a review of the literature on the elasticity of demand","volume":"35","author":"Pacula","year":"2014","journal-title":"Public Health Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00181-015-0992-1","article-title":"The price elasticity of Marijuana demand: evidence from crowd-sourced transaction data","volume":"50","author":"Davis","year":"2016","journal-title":"Empir Econ."},{"key":"B21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.drugpo.2018.03.031","article-title":"Big data on a big new market: Insights from Washington State's legal cannabis market","volume":"57","author":"Caulkins","year":"2018","journal-title":"Int J Drug Policy."},{"key":"B22","doi-asserted-by":"publisher","first-page":"102793","DOI":"10.1016\/j.drugpo.2020.102793","article-title":"Perceived importance of factors in cannabis purchase decisions: a best-worst scaling experiment","volume":"91","author":"Zhu","year":"2020","journal-title":"Int J Drug Policy."},{"key":"B23","doi-asserted-by":"publisher","first-page":"art11","DOI":"10.2202\/1935-1682.1992","article-title":"Risks and prices: the role of user sanctions in marijuana markets","volume":"10","author":"Pacula","year":"2010","journal-title":"B E J Econom Anal Policy."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2019.07.037","article-title":"The impacts of potency, warning messages, and price on preferences for Cannabis flower products","volume":"74","author":"Shi","year":"2019","journal-title":"Int J Drug Policy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1111\/add.13886","article-title":"Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state","volume":"112","author":"Smart","year":"2017","journal-title":"Addiction."},{"key":"B26","unstructured":"SchroyerJ\n            LongA\n          Cannabis sales records smashed or set in 2020, insiders expect the gains to continue MjBizDaily2021"},{"key":"B27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11121-016-0702-z","article-title":"Exploring Marijuana advertising on weedmaps, a popular online directory","volume":"18","author":"Bierut","year":"2017","journal-title":"Prev Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.drugalcdep.2017.01.017","article-title":"Marijuana advertising exposure among current marijuana users in the US Drug","volume":"174","author":"Krauss","year":"2017","journal-title":"Alcohol Depend."},{"key":"B29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s42238-020-00041-1","article-title":"A content analysis of internet information sources on medical cannabis","volume":"2","author":"Kruger","year":"2020","journal-title":"J Cannabis Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"108183","DOI":"10.1016\/j.drugalcdep.2020.108183","article-title":"Validation of secondary data sources for enumerating marijuana dispensaries in a state commercializing marijuana","volume":"215","author":"Cao","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"B31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.26828\/cannabis.2018.02.003","article-title":"Online methods for locating medical marijuana dispensaries: practical considerations for future research","volume":"1","author":"Pedersen","year":"2018","journal-title":"Cannabis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/PHH.0000000000001224","article-title":"Assessing the retail environments of licensed and unlicensed cannabis dispensaries: adapting the marijuana retail surveillance tool to inform cannabis regulation in los angeles county","volume":"27","author":"Nicholas","year":"","journal-title":"J Public Health Manag Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e16853","DOI":"10.2196\/16853","article-title":"Locating medical and recreational cannabis outlets for research purposes: online methods and observational study","volume":"22","author":"Pedersen","year":"2020","journal-title":"J Med Internet Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"102547","DOI":"10.1016\/j.drugpo.2019.08.004","article-title":"Price and product variation in Washington's recreational cannabis market","volume":"91","author":"Davenport","year":"2019","journal-title":"Int J Drug Policy."},{"key":"B35","doi-asserted-by":"publisher","first-page":"102658","DOI":"10.1016\/j.drugpo.2019.102658","article-title":"Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets","volume":"76","author":"Goodman","year":"2020","journal-title":"Int J Drug Policy"},{"key":"B36","doi-asserted-by":"publisher","first-page":"107900","DOI":"10.1016\/j.drugalcdep.2020.107900","article-title":"Modes of marijuana use - smoking, vaping, eating, and dabbing: results from the 2016 BRFSS in 12 States","volume":"209","author":"Schauer","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"B37","doi-asserted-by":"publisher","first-page":"108505","DOI":"10.1016\/j.drugalcdep.2020.108505","article-title":"Prevalence and modes of cannabis use among youth in Canada, England, and the US, 2017 to 2019","volume":"219","author":"Hammond","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"B38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10935-017-0471-x","article-title":"Early Impacts of marijuana legalization: an evaluation of prices in Colorado and Washington","volume":"38","author":"Hunt","year":"2017","journal-title":"J Prim Prev."},{"key":"B39","unstructured":"FDA Warns Company Marketing Unapproved Cannabidiol Products With Unsubstantiated Claims to Treat Cancer, Alzheimer's Disease, Opioid Withdrawal, Pain and Pet AnxietyU.S. Food and Drug Administration"},{"key":"B40","first-page":"394","article-title":"Medical fraud, mislabeling, contamination: all common in CBD products","volume":"117","author":"Evans","year":"2020","journal-title":"Mo Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"110261","DOI":"10.1016\/j.forsciint.2020.110261","volume":"310","author":"Grafinger","year":"2020","journal-title":"Cannabidiol and Tetrahydrocannabinol Concentrations in Commercially Available CBD E-Liquids in Switzerland. Forensic Sci Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/19390211.2020.1766634","article-title":"Content vs. label claims in Cannabidiol (CBD)-containing products obtained from commercial outlets in the State of Mississippi","volume":"17","author":"Gurley","year":"2020","journal-title":"J Diet Suppl"},{"key":"B43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/can.2019.0078","article-title":"An analysis of over-the-counter cannabidiol products in the United Kingdom","volume":"7","author":"Liebling","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"key":"B44","article-title":"GemmaCert Global Data Shows that 45% of THC-dominant Flowers are Mislabelled","year":"2021","journal-title":"Cision PR Newswire"},{"key":"B45","first-page":"257","article-title":"Policy responses to calls for the medical use of cannabis","volume":"88","author":"Hall","year":"2015","journal-title":"Yale J Biol Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"630602","DOI":"10.3389\/fpsyt.2021.630602","article-title":"Do cannabis users reduce their THC dosages when using more potent cannabis products? a review","volume":"12","author":"Leung","year":"2021","journal-title":"Front Psychiatry."},{"key":"B47","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1097\/j.pain.0000000000002000","article-title":"General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews","volume":"162","author":"Mohiuddin","year":"2021","journal-title":"Pain"},{"key":"B48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/wps.20735","article-title":"Assessing the public health impacts of legalizing recreational cannabis use: the US experience","volume":"19","author":"Hall","year":"2020","journal-title":"World Psychiatry."},{"key":"B49","doi-asserted-by":"publisher","first-page":"591979","DOI":"10.3389\/fpsyt.2020.591979","article-title":"Cannabis legalization and acute harm from high potency cannabis products: a narrative review and recommendations for public health","volume":"11","author":"Matheson","year":"2020","journal-title":"Front Psychiatry."},{"key":"B50","unstructured":"State of the industry report. Five Years of data reveals key trends in the cannabis cultivation market"},{"key":"B51","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3732\/ajb.91.6.966","article-title":"A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae)","volume":"91","author":"Hillig","year":"2004","journal-title":"Am J Bot."},{"key":"B52","unstructured":"403411\n            RahnB\n          Indica vs. Sativa: Understanding the Differences Between Weed Types. Leafly Holdings, Inc: Leafly272018"},{"key":"B53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.15288\/jsad.2016.77.515","article-title":"Pain, cannabis species, and cannabis use disorders","volume":"77","author":"Cohen","year":"2016","journal-title":"J Stud Alcohol Drugs."},{"key":"B54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s10194-018-0862-2","article-title":"Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort","volume":"19","author":"Baron","year":"2018","journal-title":"J Headache Pain."},{"key":"B55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.addbeh.2019.02.003","article-title":"Prevalence and correlates of medical cannabis patients' use of cannabis for recreational purposes","volume":"93","author":"Morean","year":"2019","journal-title":"Addict Behav."},{"key":"B56","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1177\/0022042616659759","article-title":"Evolution of the United States Marijuana Market in the decade of liberalization before full legalization","volume":"46","author":"Davenport","year":"2016","journal-title":"J Drug Issues."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/add.14909","article-title":"Estimation of the proportion of population cannabis consumption in Australia that is accounted for by daily users using Monte Carlo Simulation","volume":"115","author":"Chan","year":"2020","journal-title":"Addiction."},{"key":"B58","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.jpain.2019.01.010","article-title":"Pills to Pot: observational analyses of cannabis substitution among medical cannabis users with chronic pain","volume":"20","author":"Boehnke","year":"2019","journal-title":"J Pain."},{"key":"B59","doi-asserted-by":"crossref","unstructured":"HansenB\n            MillerK\n            WeberC\n          10.3386\/w23632Getting Into the Weeds of Tax Invariance. In: National Bureau of Economic Research2017","DOI":"10.3386\/w23632"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.893009\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:41:14Z","timestamp":1655451674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.893009\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":59,"alternative-id":["10.3389\/fpubh.2022.893009"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.893009","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"article-number":"893009"}}